A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Mesalamine (APRISO)

Mesalamine delayed-release tablets are indicated for the treatment of moderately active ulcerative colitis in adults.

First FDA approval1993-05-10
Generic availableYes · 23 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$454.7M in CY2024 Part D spend972K claims · 284K beneficiaries · 329 plans surveyed

Lowest NADAC
$0.104/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.443
Across all dosage forms in distribution.
Highest NADAC
$0.891
Wide spread — brand-strength NDCs still in market.
Plans with PA
1 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema12 entries indexed · 4 visible
What is Mesalamine used for?

Mesalamine delayed-release tablets are indicated for the treatment of moderately active ulcerative colitis in adults.

Is there a generic for Mesalamine?

Yes. 31 ANDAs filed at FDA, 23 generic manufacturers currently shipping.

How much does my plan pay for Mesalamine?

Across 329 Part D plans, Mesalamine averages $0.443/unit (NADAC). Lowest available: $0.104/unit. Highest in distribution: $0.891/unit.

Is Mesalamine on the FDA shortage list?

No. Mesalamine is not currently on the FDA Drug Shortage Database.

8 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Aminosalicylate2 alternatives in D1
01
Balsalazide Disodium
Aminosalicylate
$0.372Lowest NADAC
5Generic mfrs
$27.8MCY24 Part D spend
Compare →
02
Sulfasalazine
Brand: Azulfidine
$0.197Lowest NADAC
4Generic mfrs
$29.2MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.